. Our Firm continues to receive inquiries from individuals who allegedly developed bladder cancer due to Actos, and we are pleased to see this proceeding moving forward.
New York, New York (PRWEB) June 01, 2014
Thousands of Actos lawsuits (http://www.theactoslawsuitcenter.com/) that allege the use of the Type 2 diabetes medication can increase the risk that a patient will develop bladder cancer continue to move forward in a multidistrict litigation underway in U.S. District Court, Western District of Louisiana. On May 23, the Court issued an Order reappointing the litigation’s Special Master and Deputy Special Masters, who collectively are responsible for overseeing all aspects of case management, including the claims process, discovery, experts, legal issues, bellwether trial matters, and settlement negotiations. The Order points out that the Special Master and Deputy Masters were originally appointed in April 2012, and have been “extraordinarily helpful to this Court and the parties, yielding palpable benefits and cost savings.” (In re: Actos Product Liability Litigation, MDL No. 2299)
“As the Court’s Order indicates, the federal Actos litigation has grown considerably since it was established in December 2011. Our Firm continues to receive inquiries from individuals who allegedly developed bladder cancer due to Actos, and we are pleased to see this proceeding moving forward,” says Bernstein Liebhard LLP, a nationwide law firm representing the victims of defective drugs and medical devices. The Firm is currently offering free legal evaluations to individuals who were treated with Actos for a year or more, and who allegedly went on to develop bladder cancer due to their use of the drug.
Actos Bladder Cancer Allegations
According to court documents, more than 3,000 Actos bladder cancer claims are now pending in the Western District of Louisiana. All of the lawsuits allege that Takeda Pharmaceuticals and other defendants concealed data linking the use of Actos to the development of bladder cancer, and failed to provide patients and doctors with adequate warnings about this risk.
Court filings indicate that the federal litigation completed its first trial of an Actos lawsuit in April. The case ended with a jury awarding the plaintiff $1.475 million in compensatory damages, along with $9 billion in punitive damages. (Allen v. Takeda Pharmaceuticals North America Inc., 12-cv-00064).
Court records show that the Actos bladder cancer litigation has been mounting since June 2011, when the U.S. Food & Drug Administration warned that use of the medication for more than 1 year was associated with a doubling of the risk of bladder cancer. It was then that new information was added to the Actos label regarding this potential side effect.
Individuals who allegedly developed bladder cancer due to their long-term use of Actos may be entitled to compensation for their injury-related damages. To find out more about Actos lawsuits, please visit Bernstein Liebhard LLP’s website. For additional information, please call 800-511-5092 today.
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3 billion on behalf of our clients. The Firm has been named by The National Law Journal to the Plaintiffs’ Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.
Bernstein Liebhard LLP represents the victims of defective drugs and medical devices on a contingency-fee basis, and our clients are never expected to pay attorneys fees unless their case results in a successful recovery on their behalf. New York State’s contingency fee cap rules generally limit those fees to 33 1/3% of the total recovery. As a result, the Firm’s fees can be significantly lower than those assessed by attorneys in other states, which depending on the law may amount to as much as 40% or more of a plaintiff’s recovery.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2014 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Felecia L. Stern, Esq.
Bernstein Liebhard LLP